Published in Vaccine Weekly, May 11th, 2005
According to recent research published in the journal Cell Cycle, "The widely-expressed molecular chaperone heat shock protein 90 (Hsp90) regulates several important cellular processes via its repertoire of 'client' proteins."
"Signal transduction pathways controlled by Hsp90 contribute to all major components of the malignant phenotype, so Hsp90 inhibitors are under investigation as anticancer agents. Since Hsp90 is also expressed at high levels in many normal tissues, it was unclear why Hsp90 inhibitors such as 17-allylamino-geldanamycin (17-AAG) have...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly